Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 2
Treatment-assignment count: 0
Stratification count: 0
Low Public Signal
HER2 / ERBB2 amplification
NSCLC · Immune Checkpoint Inhibitor
HER2 / ERBB2 amplification is flagged as low public signal because public trials show inclusion required evidence in 2 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 2
Common snippets: MET exon 14 skipping | KRAS G12C
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT07285434 | https://clinicaltrials.gov/study/NCT04143711